Workshop & Networking by UTokyo, TMDU & Greater Tokyo Biocommunity at Cambridge

**[Date & Time]**
Tuesday, May 2, 2023  2:00-8:00PM (EDT)

**[Venue]**
Havana Room and Venture Café, at CIC (Cambridge Innovation Center) Cambridge
One Broadway, 5th Floor, Kendall Square, Cambridge, MA 02142, USA

**Live streaming available from 3:00AM on May 3 (JST)**

**[Organizers]**
The University of Tokyo, Tokyo Medical and Dental University, GTB HOTS HILL*, UTokyo IPC

**[Supporters]** JETRO, UIDP, GTB

**[Registration]** Free

**Pre-registration is required. Available from Here**

Note *Greater Tokyo Biocommunity (GTB) is an industry-academia-government network for the biotechnology industry in greater Tokyo area. https://note.com/gtb_com/m/m5447989128fd

**[Main Objective]**
Japanese research and startups in the field of biotechnology are beginning to attract attention, with Tokyo at the core of research and startups in the bio/life sciences. In order to provide an opportunity for companies, investors and researchers involved in biotechnology in Cambridge to learn more about research, biotechnology and start-ups in Tokyo, the President of the University of Tokyo, the Director of the Tokyo Medical and Dental University, as heads of the core research institutions of Tokyo’s biotech community, and their associated VC officials will visit the Cambridge Innovation Center for workshops and networking. Through this event, we hope to stimulate further attention to biotechnology in Tokyo and the university research that supports it, as well as to biotech startups in Tokyo!

**[Program]**
2:00-4:00PM  Pre-Session
Organizer/Moderator: Mark Ohori, Parnter and CIO, Life Science, UTokyo IPC

1stRound
① Introduction to UTokyo Innovation Platform Co., Ltd. (IPC)
   Kosuke Ueda, President, UTokyo IPC
② Call for Applications: UTokyo IPC’s “1stRound” Accelerator Program - Apply Now!
   Hideki Nagasaka, Manager, UTokyo IPC
   Hironori “Rick” Kobayashi, Co-Founder, CEO, Citadel AI
   Taiki Ishikura, Co-founder & CEO, Logomix, Inc.

Panel Discussion
   David Donabedian, Executive Partner,
   Interim NewCo CEO, Longwood Fund
   Shinichiro Fuse, Partner and Managing Director,
   TPG Life Sciences Investment
   Gavin Kuziel, Venture Partner, UTokyo IPC
   Jo Viney, Co-founder, President & CEO, Seismic Therapeutics

4:00-6:00PM  Workshop
① Presentation: Teruo Fujii, President, The University of Tokyo
② Show case of research & startups from GTB: UTokyo, Todai TLO, UTokyo IPC and TMDU
   Takao Someya, Executive Director, Vice President, the University of Tokyo
   Keiko Honda, Vice President, Todai TLO Ltd.
   Toshiya Watanabe, Professor, IFI the University of Tokyo
   Arinobu Tojo, Executive Director / Executive Vice President,
   Tokyo Medical and Dental University (TMDU)
   Kaori Iida, Professor, Tokyo Medical and Dental University
   -Discussion

6:00-8:00PM  Networking
** The following session will take place at 7:00PM
How does Japan create born global startup?
Summary of project research survey & Discussion
**Workshop & Networking**

b UTokyo, TMDU & Greater Tokyo Biocommunity at Cambridge

**Speakers**

2:00-4:00PM Pre-Session

**Organizer/Moderator for Panel Discussion**

Makoto (Mark) Ohiri

Makoto (Mark) OHIRI, Ph.D. Partner and CIO, Life Science, UTokyo IPC

Makoto (Mark) Ohiri, Ph.D joined UTokyo IPC in October 2020. Prior to UTokyo IPC, Mark was Executive Director, Head of Early-stage Partnering at Astellas Innovation Management LLC (Cambridge, MA), where he led a global Search, Evaluation and Transaction team and established various strategic partnerships with life science companies and academic institutions in the US, Europe, and Japan. Before that, he worked for Astellas Venture Management LLC (Menlo Park, CA) as Investment Director and

**1st Round**

**Kosuke UEDA, President, UTokyo IPC**

Master of Law at Kansai University/Juris Doctor of Seikei University/Completed the training for government officials at Ministry of Finance. Kosuke Ueda joined UTokyo IPC in 2017. After serving as CFO and Corporate Planning Partner, he was appointed President and CEO in December 2022. He worked at Sompoe Japan Insurance Inc. (currently, Sompoe Japan Nipponkoa Insurance Inc.) and the Japan Science and Technology Agency (JST). He moved to SEGAM SAMMY HOLDINGS CO., LTD as CFO, executive officer, and general manager of the subsidiary corporate planning office of SEGAM SAMMY. Supervised the administration department and concurrently served as an executive officer at the overseas subsidiary. After the experience as assistant manager of global business unit at MUSUM Group Inc., he moved to UTokyo IPC 2 years ago. Kosuke has unique background from the fact that he had played as creative producer and also as the featured actor at the theatrical group, the "start up" in entertainment field, until he was 29 years old. He achieved to grow the theatrical group to the one that could gather a few thousands of audiences while touring many music-theater shows in Kansai area. Kosuke is the self-elected singer, dancer and multi-talented man who has the various experiences from business development and management at the both private and public sectors.

**Hironori "Rick" Kobayashi, Co-Founder, CEO, Citadel AI**

CEO, Indiana Pacers Corporation 2018
SVP, Mitsubishi Corporation (America) 2010
President, Loyalty Marketing Inc.(Ponta) 1996
B.E.E, Univ of Tokyo / Joined Mitsubishi Corporation

Rick holds a degree in electronic engineering from The University of Tokyo. Later, he joined Mitsubishi Corporation and served the President of Loyalty Marketing, Inc., which is famous for the coalition program called Ponta, SVP of Mitsubishi Corporation (Americas), and CEO of Indiana Pacers Corporation in U.S. He has outstanding management skills and extensive industry knowledge ranging from IT to medical, retail and food industries.

**Hideki NAGASAKA, Manager, UTokyo IPC**

Hideki Nagasaka is the head of 1stRound, an academia-led accelerator program that supports university-related startups and commercializes university technology at The University of Tokyo (IPC) and other universities. Prior to his current role, he worked at Deloitte, where he was primarily involved in planning and executing new business models for major automotive manufacturers and startups. In addition, he co-founded an indoor drone solution startup, gaining valuable experience in entrepreneurship and fundraising.

**Taiki Ishikura, Co-founder & CEO, Logomix, Inc.**

LinkedIn Profile: https://www.linkedin.com/in/taiki-ishikura/

Taiki is a serial biotech entrepreneur. Taiki is CEO & Co-Founder of Logomix, a synthetic biology company developing human cells with unprecedented precision and higher-order genetic complexity for new therapeutics. Formerly, Taiki worked at JMODD as CBO, a medtech incubator in Tokyo commercializing early-stage technologies in therapeutic and diagnostic devices. He also served as Board Director leading cancer genomics business at PS, Inc., a joint venture by Sony, Illumina, and M3 ($708 medical platform). Prior to JMODD and PS, he worked at M3 in a variety of positions spanning new business development and post-merger integration. Prior to M3, he was a co-founder of Aqumen Biopharmaceuticals K.K., an ophthalmology biotech startup.

**Panel Discussion**

**David H. DONABEDIAN, Ph.D., Executive Partner, Interim NeoWCO CEO, Longwood Fund**

Dr. David H. Donabedian is an Executive Partner at Longwood Fund. He joined the fund in 2015 as a Venture Partner and has over 20 years of professional experience and expertise leading business development, venture teams and demonstrated track record of company creation. He is a co-founder and start-up CEO of DEM BioPharma, start-up CEO of Longwood-founded ImmuneX, founding CEO of Longwood-founded Axial Therapeutics and founding executive of Ayclone Therapeutics. Prior to joining Longwood, Dr. Donabedian held various leadership roles at biopharmaceutical companies including AbbVie (NASDAQ:ABBV) and GlaxoSmithKline (NYSE: GSK). At AbbVie he served as Vice President and Global Head of Ventures and Early-Stage Collaborations where he led a global team that completed significant transactions across multiple therapeutic areas and stages of development. Prior to AbbVie, Dr. Donabedian served as the interim President of Global New Deal Strategy and Development at GlaxoSmithKline, VP of Business Development, Surface Genix (sold to Kmadon, acquired by Sanofi, for $1.9B) and Senior Manager at Accenture’s Strategic Services Consulting Group. Dr. Donabedian holds a B.A. in Chemistry from St. Anselm College, a Ph.D. in Polymer Chemistry from the University of Massachusetts, Amherst, and an MBA from UNC- Chapel Hill. He currently serves on the Board of Aonuca Inc. and Ayclone Therapeutics, Inc.

**Shinichiro Fuse, Ph.D., Partner and Managing Director, TPG Life Sciences Investment**

Dr. Shinichiro (Shin) Fuse, is Partner and Managing Director at TPG Life Sciences Innovation. He co-leads the life sciences venture investments at TPG, and serves on the Board of Directors at Santa Ana Bio. Previously, he was Managing Director at MPM Capital, where he served on the investment committee of the Oncology Impact Fund (DIF) and Bi Ventures Fund. Shin served on the Board of Directors of Oora Therapeutics, IOM Therapeutics, Triplet Therapeutics and a stealth newcomer, and as a board observer for ElevateBio and Reare Therapeutics. Shin also played operational roles at MPM portfolio companies as the interim CEO of Ora Therapeutics and interim/founding CEO of Business Development at ElevateBio. Prior to joining MPM, he was Director of Business Development at bluebird bio, where he was instrumental in executing and managing key industry and academic partnerships in the fields of cell and gene therapy, cancer immunotherapy and gene editing. Previously, he was at Campbell Alliance (Synexus Health) as a life science strategy consultant, and an associate at PureTech. He currently serves on the Board of Advisors of the Guarini School of Graduate and Advanced Studies at Dartmouth College. Shin received his Ph.D. in Microbiology and Immunology from Dartmouth College, an M.S. in Biomedical Science from the University of Tokyo, and a B.Eng. in Applied Chemistry from Keio University in Japan.

**Gavin KUZIEL, Venture Partner, UTokyo IPC**

Gavin Kuziel began working with UTokyo IPC in October 2022. Based in Boston, Massachusetts, Gavin is focused on identifying opportunities for scientific collaboration between Boston and Tokyo. Alongside his work with UTokyo IPC, Gavin is currently completing his doctoral studies in chemical biology at Harvard University where he studies the molecular interactions between the human gut microbiome and diet in health and disease. Prior to Harvard, Gavin completed his undergraduate studies in the Department of Chemistry at the University of Tokyo where he developed molecular glues for therapeutically relevant protein-protein interactions in the laboratory of Professor Hiroaki Suga.

**Jo VINEY, Ph.D., Co-founder, President & CEO, Seismic Therapeutics**

Dr Jo Viney, Ph.D is a co-founder and CEO of Seismic Therapeutics, the machine learning immunology company developing medicines for autoimmune disease. A seasoned biotech executive and entrepreneurial scientist, she has co-founded 3 startup companies in MA - the first of which, Pandion Therapeutics, was acquired by Merck in 2021 for $1.85B.

Prior to Pandion she held research leadership positions and contributed to the drug discovery disciplines at Biogen and Amgen. Jo is a big advocate for workplace inclusivity and regularly volunteers her time with a number of organizations focused on increasing diversity in STEM careers.
Workshop & Networking by UTokyo, TMDU & Greater Tokyo Biocommunity at Cambridge

Speakers

4:00-6:00PM Workshop

Teruo Fujii, President, the University of Tokyo (UTokyo)
Dr. Teruo Fujii became the 31st President of the University of Tokyo (UTokyo) on April 1, 2021, with a six-year term. He was previously the Executive Vice President in charge of finance and external relations for the university. He also served as the Director General of the Institute of Industrial Sciences (IIS) of the university from 2015 to 2018. He received his Ph.D. in engineering from UTokyo in 1993 and held research positions at IIS and RIKEN prior to becoming a professor of IIS in 2007. Dr. Fujii’s research specializes in applied microfluidics systems and underwater technology.

Keiko Honda, Vice President, Todai TLO Ltd.
Keiko Honda is Vice President of the technology licensing organization of the University of Tokyo (Todai TLO) since 2018. She has a Ph.D. in Medical Science from the University of Tokyo and has several years of experience in research. She is also a certified patent agent in Japan and has several years of experience in patent prosecution at a patent firm. She has been seconded at Todai TLO since 2001. She is certified RTTP.

Takao Someya, Executive Director and Vice President, Professor, the University of Tokyo
Dr. Takao Someya is Executive Director and Vice President (responsibility: start-up, value of knowledge) and Professor, the University of Tokyo. He is recognized as an inventor of electronic skins, which was featured by Time Magazine as one of the best inventions of the year in 2005. He earned his doctoral degree in engineering from the University of Tokyo and held additional positions as Global Scholar at Princeton University, Global Foundaries Visiting Professor at National University of Singapore, and Hans Fisher Senior Fellow at Technical University of Munich. He served as Dean of Graduate School of Engineering at the University of Tokyo. He is the 2024 President of Materials Research Society (MRS) in the US.

Arinobu Tojo, M.D., D.M.Sc Executive Director / Executive Vice President, Tokyo Medical and Dental University (TMDU)
2005 Professor, Division of Molecular Therapy, Institute of Medical Science, The University of Tokyo (IMSUT)
2012-2018 Chair, Advanced Clinical Research Center, IMSUT
2018-2021 Director, IMSUT Hospital
2021-2022 Deputy Director / Vice President, TMDU
2022- Professor Emeritus, UTokyo
2022- Executive Director / Executive Vice President, TMDU

Toshiya Watanabe, Executive Director and Vice President, Professor, the University of Tokyo
Toshiya Watanabe is currently Executive Director and Vice President of the University of Tokyo. He has graduated from Tokyo Institute of Technology and has a PhD degree in 1994. He has experienced R&D and Executive Manager for a manufacturing company from 1985 to 2001. He has been invited to be a professor of The University of Tokyo from 2001. He is currently a Professor of Institute for Future Initiatives of The University of Tokyo. He is serving Committee Chairman of Intellectual Property Strategy Headquarters of the government.

Yoichi Okumura, Director, Division of University Corporate Relations, the University of Tokyo
Yoichi Okumura has master degrees of both law and pharmacy. He had worked for Takeda Pharmaceutical Company, Ltd. for more than 30 years in its functions of Intellectual Property and Business Development such as product licenses and M&A. During his Business Development carrier, he drove several product licensing deals as a negotiation leader and worked on some M&A activities including some in Cambridge, MA. Within capacity of his last Takeda carrier as a Global Head of IP, he played several leader roles of global industry IP associations. Soon after leaving Takeda, he became a CEO of a bio-venture, SCOHIA PHARMA, Inc. until mid 2022.

Kaori Iida, Ph.D Professor / Director, Institute of Innovation, Tokyo Medical and Dental University (TMDU)
2013- Professor, Director, TMDU
2011-2013 Associate Professor, Director, TMDU
2010-2011 Junior Associate Professor, Intellectual Property Division, TMDU
2008-2010 Assistant Professor, Intellectual Property Division, TMDU
2005-2008 Legal research Assistant, TMDU